Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$21.53 - $26.8 $19,161 - $23,852
-890 Reduced 1.55%
56,703 $1.31 Million
Q4 2022

Feb 13, 2023

BUY
$18.63 - $27.35 $232,930 - $341,957
12,503 Added 27.73%
57,593 $1.51 Million
Q3 2022

Nov 14, 2022

SELL
$17.51 - $23.37 $23,218 - $30,988
-1,326 Reduced 2.86%
45,090 $886,000
Q1 2022

May 16, 2022

BUY
$12.02 - $16.69 $557,920 - $774,683
46,416 New
46,416 $760,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.